# Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Study · id `cardio:ct-nct04029363` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04029363](<https://clinicaltrials.gov/study/NCT04029363>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04029363

Browse, organ or system: Heart  
Browse, condition area: Heart failure; Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT04029363. Allocation not applicable; no masking; primary purpose treatment. Start 2019-05-28 (actual); primary completion 2026-12-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT04029363, source copy `cardio:ctgov-nct04029363-2025-09-15`, retrieved 2026-10-26)
- Started: 2019-05-28 (actual) (ClinicalTrials.gov record NCT04029363, source copy `cardio:ctgov-nct04029363-2025-09-15`, retrieved 2026-10-26)
- Primary completion: 2026-12-15 (anticipated) (ClinicalTrials.gov record NCT04029363, source copy `cardio:ctgov-nct04029363-2025-09-15`, retrieved 2026-10-26)
- Completion: 2031-12-15 (anticipated) (ClinicalTrials.gov record NCT04029363, source copy `cardio:ctgov-nct04029363-2025-09-15`, retrieved 2026-10-26)
- Countries: Australia; Belgium; France; Germany; Poland; Singapore; United Kingdom (ClinicalTrials.gov record NCT04029363, source copy `cardio:ctgov-nct04029363-2025-09-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04029363-2025-09-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk
- Condition: Mitral Regurgitation
- Intervention (Device): HighLife Transcatheter Mitral Valve Replacement
- Lead sponsor: HighLife SAS
- Lead sponsor class: INDUSTRY
- Collaborator: ICON plc
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Mitral regurgitation (`cardio:mitral-regurgitation`)
- Registry lists this organization as a collaborator: ICON plc (`cardio:org-icon-plc`)

## Provenance

Content hash: d58b5f55290c282ebeab51a66376f03f04af884d66ce88543a220c3eedf9b8fe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
